Furthermore, it has been found that ATR inhibitors are selectively toxic to cancer cells harboring mutations in the ATM tumor suppressor, in part because ATM and ATR share some overlapping targets (Kantidze et al. 2018). The gene discussed is ATM; the disease is neoplasm.